Epizyme to Present Data on Preclinical Pipeline at the American Association for Cancer Research (AACR) Annual Meeting

Cambridge, Mass., March 18, 2015 - Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from its preclinical pipeline will be presented during the American Association for Cancer Research (AACR) Annual Meeting, to be held April 18-25 in Philadelphia, Pa. The presentations include findings on four new epigenetic targets: CARM1, PRMT6, SMYD3 and SETDB1. The Company will also present new pre-clinical data on DOT1L.

CARM1 preferentially methylates H3R17 over H3R26 through a random kinetic mechanism, Abstract #97
Session Title: Histone Methylation and Acetylation
Presentation Time: Sunday, Apr 19, 2015, 1:00 p.m. - 5:00 p.m.
Poster Board Number: 6

Crystal structures of CARM1 bound to sinefungin and diverse peptide substrates, Abstract #2437
Session Title: PO.CH02.01. Chemical Biology and Structure-Function Studies of Cancer Mechanisms
Presentation Time: Monday, April 20, 1:00 p.m. - 5:00 p.m.
Poster Board Number: 2

Identification of the first PRMT6 inhibitor small molecule tool compound, Abstract #5376
Session Title: PO.ET06.08. Histone Deacetylase Inhibitors, Methyltransferase Inhibitors, and Other Targets
Presentation Time: Wednesday, April 22, 8:00 a.m. - 12:00 p.m.
Poster Board Number: 6

Characterization of acquired EPZ-5676 resistance in cell line models of MLL rearranged leukemia, Abstract #2701
Session Title: PO.ET04.01. Resistance to Pathway-Targeted Therapeutics 1
Presentation Time: Monday, April 20, 1:00 p.m. - 5:00 p.m.
Poster Board Number: 23

DOT1L inhibitor EPZ-5676 synergizes with cytarabine and azacitidine in preclinical model of MLL-rearranged leukemia, Abstract #5383
Kinetic Mechanism of the Lysine Methyltransferase SMYD3 Using MAP3K2 Protein Substrate, Abstract #2144
Session Title: Ras, Raf, ERK, and PI3K Pathway Signaling
Presentation Time: Monday, April 20, 1:00 p.m. - 5:00 p.m.
Poster Board Number: 7

ATF7IP Does Not Alter the Substrate Specificity of the Lysine Methyltransferase SETDB1, Abstract #104
Session Title: Histone Methylation and Acetylation
Presentation Time: Sunday, April 19, 2015, 1:00 p.m. - 5:00 p.m.
Poster Board Number: 13

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation of future clinical studies or expansion of ongoing clinical studies, availability and timing of data from ongoing clinical studies, expectations for regulatory approvals, development progress of the Company’s companion diagnostics, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates.
or companion diagnostics and other factors discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission in on March 12, 2015. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Media/Investors:
Manisha Pai
Epizyme, Inc.
617.229.7560
mpai@epizyme.com